Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 246

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 246
---
 Forma Combined Consolidated Statement of Operations and under “ Accumulated Deficit” in the Pro Forma Combined Consolidated Statement of Financial Position as of June 30, 2024. Additionally, since APx’s estimated transaction costs were not accrued in its historical financial statements as of June30, 2024, this pro forma adjustment includes the recognition of a liability of $5.88million, considering that said amount is within the limit of “ SPAC Transaction Expenses” that will be assumed by OmnigenicsAI, provided for in the Business Combination Agreement. See Note (1) under “ Adjustments to Unaudited Pro Forma Combined Consolidated Statement of Operations for the Year Ended June 30, 2024.” In consequence, the effect of this adjustment on Share premium ($55.8million) arises from the difference between the listing services ($61.7million) and the liability for estimated APx transaction costs ($5.9million), which will be assumed by OmnigenicsAI. (6)During the second half of 2024, OmnigenicsAI entered into an intercompany loan agreement with the Parent, of which $47,693 has been disbursed. The terms of this intercompany loan agreement include an interest rate of 6.5% per annum, with a maturity date of May 1, 2025. For pro forma purposes, this borrowing is treated as if it occurred on July 1, 2023, with accrued interest of $3,100 as of June 30, 2024. Under the terms of this intercompany loan agreement, the Parent is allowed to make payments on behalf of the Company. Additionally, Heritas Argentina, a subsidiary of OmnigenicsAI, received financing from existing credit facilities after June 30, 2024, in the amount of $69,863 from the Parent, in an amount of $215,322 from Bioceres S.A. and in an amount of $29,762 from CIBIC. The terms of these loan agreements include interest rates of 6.5% per annum, with maturity dates ranging from January 2028 to September 2028. For pro forma purposes, said financings are treated as if they were performed on July 1, 2023. In consequence, as of June 30, 2024, accrued interests of these borrowings amounted to $20,472.

110

A summary of said financings is disclosed in table below:

| Date                                                                   
 08